News

ISAR-REACT 4 Trial Backs Bivalirudin for NSTEMI


 

FROM THE ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION

The full results of the trial were simultaneously published online in the New England Journal of Medicine (2011 Nov. 13 [doi:10.1056/NEJMoa1109596]).

Nycomed Pharma sponsored the trial. Dr. Kastrati reported speaker fees or honoraria from Abbott, AstraZeneca, Bristol-Myers Squibb, Cordis, Daichii Sankyo/Lilly, and Medtronic. Dr. Bhatt reported research grants from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi-Aventis, and The Medicines Company. Dr. Harrington is an adviser and/or consultant to AstraZeneca, Johnson & Johnson, Merck, Novartis, Pfizer, Portola, Regado, and Sanofi-Aventis.

Pages

Recommended Reading

Benefits of Perioperative Statins Borne Out in Trial
MDedge Internal Medicine
In-Hospital Mortality Risk Increases With DIDO Time for STEMI Patients
MDedge Internal Medicine
Rules Identify Which Chest Pain Patients Can Be Sent Home
MDedge Internal Medicine
Rule Predicts Which ED Patients Need an Immediate ECG
MDedge Internal Medicine
Healthy Lifestyle Cuts Women's Sudden Cardiac Death Risk by 92%
MDedge Internal Medicine
Quick Cooling With Therapeutic Hypothermia Improves Neurologic Outcomes in Certain Patients
MDedge Internal Medicine
'Late' PCI Still Common Though Guidelines Advise Against It
MDedge Internal Medicine
High Platelet Reactivity Signals High Risk of Ischemic Events
MDedge Internal Medicine
Evidence-Based Cardiac Imaging Getting Closer
MDedge Internal Medicine
Defensive Medicine Factors Into Cardiac Admissions
MDedge Internal Medicine